DiaSorin reported strong Q3 results with growth across the board, i.e. both COVID-19 and non-COVID offerings. Although margins came under pressure, it is likely to be a transient concern. Hence, management upgraded its 2021 outlook. Overall, with of a combination of healthy demand fundamentals, sustained innovation and the testing sector still attracting M&A interest, DiaSorin remains attractive at current levels.
12 Nov 2021
Healthy performance led guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy performance led guidance upgrade
- Published:
12 Nov 2021 -
Author:
Anas PATEL -
Pages:
3
DiaSorin reported strong Q3 results with growth across the board, i.e. both COVID-19 and non-COVID offerings. Although margins came under pressure, it is likely to be a transient concern. Hence, management upgraded its 2021 outlook. Overall, with of a combination of healthy demand fundamentals, sustained innovation and the testing sector still attracting M&A interest, DiaSorin remains attractive at current levels.